![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Lixisenatide is a human glucagon-like peptide-1 receptor agonist for the once-daily treatment of Type 2 diabetes mellitus (T2DM). Lixisenatide is based on the structure of exendin-4 (1-39) with C-terminal modification. Clinical trials involving patients with T2DM have provided evidence for improved glucose tolerance, weight loss and lowered hemoglobin A1c (HbA1c) causing a significantly higher percentage of patients to achieve target HbA1c compared with placebo. This article reviews the clinical pharmacology of lixisenatide as well as the GetGoal clinical trial program that aims to make lixisenatide available for the treatment of patients with T2DM.
Financial & competing interests disclosure
Filip K Knop has served as a consultant for AstraZeneca and Eli Lilly. Tina Vilsbøll has served as a consultant for Novo Nordisk, Merck Sharp Dome and Eli Lilly. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.